Eri Srivatsan

Eri Srivatsan


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
JCJon Mallen-St Clair
Jon Mallen-St Clair
MAMustafa Alani
Mustafa Alani
MWMarilene B. Wang
Marilene B. Wang
ESEri Srivatsan
Eri Srivatsan

19 May 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
SBSaroj K. Basak
Saroj K. Basak
AZAlborz Zinabadi
Alborz Zinabadi
AWArthur W. Wu
Arthur W. Wu
NVNatarajan Venkatesan
Natarajan Venkatesan
VDVictor M. Duarte
Victor M. Duarte
ESEri Srivatsan
Eri Srivatsan
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer, with 600,000 new cases every year worldwide. Although chemotherapeutics exist, five-year survival is only 50%. New strategies to overcome drug resistance are required to improve HNSCC treatment. Curcumin-difluorinated (CDF), a synthetic analog of curcumin, was packaged in liposomes and used to evaluate growth inhibition of cisplatin resistant HNSCC cell lines CCL-23R and UM-SCC-1R generated from the parental cell lines CCL-23 and UM-SCC-1 respectively. Growth inhibition in vitro and expression levels of the CD44 (cancer stem cell marker), cytokines, and growth factors were investigated after liposomal CDF treatment. The in vivo growth inhibitory effect of liposomal CDF was evaluated in the nude mice xenograft tumor model of UM-SCC-1R and the inhibition of CD44 was measured. Treatment of the resistant cell lines in vitro with liposomal CDF resulted in a statistically significant growth inhibition (p < 0.05). The nude mice xenograft study showed a statistically significant tumor growth inhibition of UM-SCC-1R cells and a reduction in the expression of CD44 (p < 0.05), indicating an inhibitory effect of liposomal CDF on CSCs. Our results demonstrate that delivery of CDF through liposomes may be an effective method for the treatment of cisplatin resistant HNSCC.

26 October 2022 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
JKJames J. Kang
James J. Kang
AKAlbert Ko
Albert Ko
SKSang Hoon Kil
Sang Hoon Kil
JCJon Mallen-St. Clair
Jon Mallen-St. Clair
DSDaniel Sanghoon Shin
Daniel Sanghoon Shin
ESEri Srivatsan
Eri Srivatsan

1 December 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MVMysore S. Veena
Mysore S. Veena
SRSantanu Raychaudhuri
Santanu Raychaudhuri
SBSaroj K. Basak
Saroj K. Basak
NVNatarajan Venkatesan
Natarajan Venkatesan
PKParameet Kumar
Parameet Kumar
ESEri Srivatsan
Eri Srivatsan
We have observed over expression of PACS-1, a cytosolic sorting protein in primary cervical tumors. Absence of exonic mutations and overexpression at the RNA level suggested a transcriptional and/or post transcriptional regulation. UCSC genome browser analysis of PACS-1 mRNA revealed two 8 base target sequences at the 3’ terminus for hsa-miR-34a and hsa-miR-449a. Quantitative RT-PCR and northern blot studies showed reduced or loss of expression of the two miRNAs in cervical cancer cell lines and primary tumors indicating dysregulation of these two miRNAs in cervical cancer. Loss of PACS-1 with siRNA or exogenous expression of hsa-miR-34a or hsa-miR-449a in HeLa and SiHa cervical cancer cell lines resulted in DNA damage response (DDR), S-phase cell cycle arrest and reduction in cell growth. Furthermore, the siRNA studies showed that loss of PACS-1 expression was accompanied by increased nuclear γH2AX expression, K-382-p53 acetylation and genomic instability. PACS-1 re-expression through LNA-hsa-anti-miR-34a or 449a or PACS-1 cDNA transfection led to the reversal of DDR and restoration of cell growth. Release of cells post 24_h serum starvation showed PACS-1 nuclear localization at G1-S phase of the cell cycle. Our results therefore indicate that the loss of hsa-miR-34a and hsa-miR-449a expression in cervical cancer leads to overexpression of PACS-1 and suppression of DNA damage response resulting in the development of chemo-resistant tumors.

29 March 2016 in Human Genetics
Verified
Journal Article
Closed access
PDF file
JKJames J. Kang
James J. Kang
ILIsabelle Y. Liu
Isabelle Y. Liu
MWMarilene B. Wang
Marilene B. Wang
ESEri Srivatsan
Eri Srivatsan

1 June 2016 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
HSHendrick Soh
Hendrick Soh
NVNatarajan Venkatesan
Natarajan Venkatesan
MVMysore S. Veena
Mysore S. Veena
SRSandhiya Ravichandran
Sandhiya Ravichandran
AZAlborz Zinabadi
Alborz Zinabadi
ESEri Srivatsan
Eri Srivatsan
We and others have shown that cystatin E/M gene is inactivated in primary human tumors pointing to its role as a tumor suppressor gene. However, the molecular mechanism of tumor suppression is not yet understood. Using plasmid directed cystatin E/M gene overexpression, lentiviral mediated tetracycline inducible vector system and HPV 16 E6 and E7 gene immortalized normal human epidermal keratinocytes, we demonstrate intracellular and non-cell autonomous apoptotic growth inhibition of tumor cell lines and that growth inhibition is associated with cytoplasmic retention of NF-κB. We further demonstrate decreased phosphorylation of IKKβ and IκBα in the presence of TNFα confirming the role of cystatin E/M in the regulation of NF-κB signaling pathway. Growth suppression of nude mouse xenograft tumors carrying a tetracycline inducible vector system was observed with the addition of doxycycline in drinking water confirming cystatin E/M as a tumor suppressor gene. Finally, immunohistochemical analysis of cervical carcinoma in situ and primary tumors have shown statistically significant inverse relationship between the expression of cystatin E/M and cathepsin L and direct relationship between the loss of cystatin E/M expression and nuclear expression of NF-κB. We therefore propose that cystatin E/M suppressor gene plays an important role in the regulation of NF-κB.